Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Jul 28, 2024 5:33pm
182 Views
Post# 36151887

Pete the Paid Pumper

Pete the Paid PumperYou really need to take a breath and get a life Pete. I hope you are getting paid well to go through the news tab and copy and paste.

We all know the news and we all thought the news would move the share price but in fact the share price is down 50% over the past two years.

You are polluting the board with old news, facts we all know.

You are doing something management has failed to do, that is create an effective investor deck and presentation. All this information and news is positive you regurgitate on this board but facts are this board is not the target audience Arch needs.

Arch management has done many great things as your copy and paste clearly demonstrates and management has put their money where their mouth is and have huge skin in the game.

I have no doubt you are being paid the recycle old news to believers but management has fsiled miserably at attracking buyers, promoting the story.

There is a reason why we are valued at a fraction of similar staged peers. Nobody know the story of Arch and science behind it.
<< Previous
Bullboard Posts
Next >>